Cargando…

Drug Repositioning and Subgroup Discovery for Precision Medicine Implementation in Triple Negative Breast Cancer

SIMPLE SUMMARY: The heterogeneity of complicated diseases like cancer negatively affects patients’ responses to treatment. Finding homogeneous subgroups of patients within the cancer population and finding the appropriate treatment for each subgroup will improve patients’ survival. In this study, we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al-Taie, Zainab, Hannink, Mark, Mitchem, Jonathan, Papageorgiou, Christos, Shyu, Chi-Ren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699385/ https://www.ncbi.nlm.nih.gov/pubmed/34944904 http://dx.doi.org/10.3390/cancers13246278

Ejemplares similares

Immune-Related Gene Signatures to Predict the Effectiveness of Chemoimmunotherapy in Triple-Negative Breast Cancer Using Exploratory Subgroup Discovery
por: Kholod, Olha, et al.
Publicado: (2022)

Identification of Immuno-Targeted Combination Therapies Using Explanatory Subgroup Discovery for Cancer Patients with EGFR Wild-Type Gene
por: Kholod, Olha, et al.
Publicado: (2022)

Exploratory Data Mining for Subgroup Cohort Discoveries and Prioritization
por: Liu, Danlu, et al.
Publicado: (2020)

Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment
por: Anselmino, L. E., et al.
Publicado: (2021)

REDESIGN: RDF–based Differential Signaling Framework for Precision Medicine Analytics
por: Al–Taie, Zainab, et al.
Publicado: (2018)

Comprehensive metabolomics expands precision medicine for triple-negative breast cancer
por: Xiao, Yi, et al.
Publicado: (2022)

Precision medicine based on tumorigenic signaling pathways for triple-negative breast cancer
por: Wu, Nan, et al.
Publicado: (2018)

Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions
por: Hossain, Fokhrul, et al.
Publicado: (2021)

Repositioning Natural Products in Drug Discovery
por: Rastelli, Giulio, et al.
Publicado: (2020)

Drug repositioning in drug discovery of T2DM and repositioning potential of antidiabetic agents
por: Zhu, Sha, et al.
Publicado: (2022)

Impact of Precision Medicine on Drug Repositioning and Pricing: A Too Small to Thrive Crisis
por: Tiriveedhi, Venkataswarup
Publicado: (2018)

A medicinal chemistry perspective of drug repositioning: Recent advances and challenges in drug discovery
por: Pillaiyar, Thanigaimalai, et al.
Publicado: (2020)

Immunogenomic pathways associated with cytotoxic lymphocyte infiltration and survival in colorectal cancer
por: Shen, Yuanyuan, et al.
Publicado: (2020)

Expression of VEGF and Semaphorin Genes Define Subgroups of Triple Negative Breast Cancer
por: Bender, R. Joseph, et al.
Publicado: (2013)

Drug repositioning for personalized medicine
por: Li, Yvonne Y, et al.
Publicado: (2012)

Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type
por: Subhan, Md Abdus, et al.
Publicado: (2023)

TBX21 Methylation as a Potential Regulator of Immune Suppression in CMS1 Subtype Colorectal Cancer
por: Shen, Yuanyuan, et al.
Publicado: (2022)

Drug repositioning can accelerate discovery of pharmacological chaperones
por: Hay Mele, Bruno, et al.
Publicado: (2015)

Large-scale Direct Targeting for Drug Repositioning and Discovery
por: Zheng, Chunli, et al.
Publicado: (2015)

DrugCentral 2021 supports drug discovery and repositioning
por: Avram, Sorin, et al.
Publicado: (2020)

The ACCOuNT Consortium: A Model for the Discovery, Translation, and Implementation of Precision Medicine in African Americans
por: Friedman, Paula N., et al.
Publicado: (2019)

Triple-Negativity Identifies a Subgroup of Patients with Better Overall Survival in Essential Thrombocythemia
por: Santoro, Marco, et al.
Publicado: (2022)

Molecular subtypes and precision treatment of triple-negative breast cancer
por: Zhao, Shen, et al.
Publicado: (2020)

Recent Advances in Drug Repositioning for the Discovery of New Anticancer Drugs
por: Shim, Joong Sup, et al.
Publicado: (2014)

Drug repositioning: Progress and challenges in drug discovery for various diseases
por: Hua, Yi, et al.
Publicado: (2022)

The 3′UTR signature defines a highly metastatic subgroup of triple-negative breast cancer
por: Wang, Lei, et al.
Publicado: (2016)

CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer
por: Craven, Kelly E., et al.
Publicado: (2021)

Drug Repositioning Discovery for Early- and Late-Stage Non-Small-Cell Lung Cancer
por: Huang, Chien-Hung, et al.
Publicado: (2014)

Enabling Comprehension of Patient Subgroups and Characteristics in Large Bipartite Networks: Implications for Precision Medicine
por: Bhavnani, Suresh K., et al.
Publicado: (2017)

Current Concepts in Pharmacometabolomics, Biomarker Discovery, and Precision Medicine
por: Beger, Richard D., et al.
Publicado: (2020)

Editorial: Computational Approaches in Drug Discovery and Precision Medicine
por: Huang, Zunnan, et al.
Publicado: (2021)

Introduction to this Special Issue: “Biomarker Discovery and Precision Medicine”
por: Fang, Bingliang
Publicado: (2020)

Advances of Osteosarcoma Models for Drug Discovery and Precision Medicine
por: Tan, Linyun, et al.
Publicado: (2023)

DISGROU: an algorithm for discontinuous subgroup discovery
por: Eugenie, Reynald, et al.
Publicado: (2021)

Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial
por: Jiang, Yi-Zhou, et al.
Publicado: (2020)

The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer
por: Divoux, Jordane, et al.
Publicado: (2023)

Discovery of therapeutic agents targeting PKLR for NAFLD using drug repositioning
por: Zhang, Cheng, et al.
Publicado: (2022)

Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment
por: Masci, Domiziana, et al.
Publicado: (2023)

Clinical Implementation of Precision Medicine in Gastric Cancer
por: Jeon, Jaewook, et al.
Publicado: (2019)

Repositioning: the fast track to new anti-malarial medicines?
por: Lotharius, Julie, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_voc14aj2br0i9vd96ahegjn7ue